Skip to main content
. 2021 Jan 19;10:607349. doi: 10.3389/fonc.2020.607349

Figure 6.

Figure 6

The clinical outcome following immune checkpoint therapy in the head and neck squamous cell carcinoma (HNSCC) patient cohort. [non-progressors (NP) or progressive disease (PD)] was measured per antibody target. ns=not significant p>0.05, *indicates statistical significance p ≤0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.